Skip to content

A prospective study of the diagnostic rate and safety of rapid on site evaluation combined with endobronchial ultrasound-guided transbronchial lung biopsy for peripheral pulmonary lesions

A prospective study of the diagnostic rate and safety of rapid on site evaluation combined with endobronchial ultrasound-guided transbronchial lung biopsy for peripheral pulmonary lesions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17013526
Enrollment
Unknown
Registered
2017-11-24
Start date
2017-12-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral pulmonary disease

Interventions

Gold Standard:Pathological diagnosis
on&#32
evaluation&#32
combined&#32
with&#32
lung&#32
biopsy

Sponsors

The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Recently CT display Peripheral pulmonary lesions no less than 8mm and no more than 3cm, for the first time for transbronchial lung biopsy patients; 2. Aged 18 years and older; 3. Can cooperate the Bronchoscopy successfully.

Exclusion criteria

Exclusion criteria: 1. Can not cooperate the Bronchoscopy successfully; 2. Patients with contraindications associated with bronchoscopy; 3. Patients who were allergic to the drugs (including lidocaine, atropine, and benzo two nitrogen); 4. There were obvious bullae and bronchiectasis in the target site of biopsy; 5. Those who with unable correct the bleeding tendency or coagulopathy or need to continue to take anticoagulants; 6. A history of severe COPD or asthma; 7. The patient has been confirmed by pathology.

Design outcomes

Primary

MeasureTime frame
Diagnosis rate;

Secondary

MeasureTime frame
Complication rate;

Countries

China

Contacts

Public ContactZhou Rui

The Second Xiangya Hospital, Central South University

zhourui2355@sina.com+86 13607430517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026